MX367165B - Formulaciones farmacéuticas para administración subcutánea de furosemida. - Google Patents

Formulaciones farmacéuticas para administración subcutánea de furosemida.

Info

Publication number
MX367165B
MX367165B MX2015014064A MX2015014064A MX367165B MX 367165 B MX367165 B MX 367165B MX 2015014064 A MX2015014064 A MX 2015014064A MX 2015014064 A MX2015014064 A MX 2015014064A MX 367165 B MX367165 B MX 367165B
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulations
furosemide
subcutaneous administration
aminomethane
hydroxymethyl
Prior art date
Application number
MX2015014064A
Other languages
English (en)
Spanish (es)
Other versions
MX2015014064A (es
Inventor
A Michaels Scott
Muntendam Pieter
R Larsen Glenn
Original Assignee
Scpharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scpharmaceuticals Inc filed Critical Scpharmaceuticals Inc
Publication of MX2015014064A publication Critical patent/MX2015014064A/es
Publication of MX367165B publication Critical patent/MX367165B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2015014064A 2013-04-05 2014-04-03 Formulaciones farmacéuticas para administración subcutánea de furosemida. MX367165B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361808962P 2013-04-05 2013-04-05
PCT/US2014/032800 WO2014165660A1 (en) 2013-04-05 2014-04-03 Pharmaceutical formulations for subcutaneous administration of furosemide

Publications (2)

Publication Number Publication Date
MX2015014064A MX2015014064A (es) 2017-04-13
MX367165B true MX367165B (es) 2019-08-07

Family

ID=51659206

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014064A MX367165B (es) 2013-04-05 2014-04-03 Formulaciones farmacéuticas para administración subcutánea de furosemida.

Country Status (14)

Country Link
US (5) US9884039B2 (https=)
EP (3) EP2981258B8 (https=)
JP (2) JP6415535B2 (https=)
KR (2) KR102493735B1 (https=)
CN (1) CN105431145B (https=)
AU (1) AU2014248164B2 (https=)
CA (1) CA2908935C (https=)
DK (1) DK2981258T3 (https=)
ES (1) ES2823589T3 (https=)
IL (1) IL241917B (https=)
MX (1) MX367165B (https=)
PT (1) PT2981258T (https=)
SG (2) SG11201508251RA (https=)
WO (1) WO2014165660A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2981258T (pt) * 2013-04-05 2020-10-19 Scpharmaceuticals Inc Formulações farmacêuticas para administração subcutânea de furosemida
DE102014115951A1 (de) 2014-11-03 2016-05-04 Merlion Pharmaceuticals Pte Ltd. Zusammensetzungen, die Finafloxacin und Tris enthalten
ES3041602T3 (en) 2018-12-10 2025-11-13 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US11246851B2 (en) 2019-01-04 2022-02-15 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US12397005B2 (en) 2019-01-04 2025-08-26 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
PH12021551811A1 (en) 2019-01-31 2022-03-21 Scpharmaceuticals Inc Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
WO2022031959A1 (en) 2020-08-05 2022-02-10 Scpharmaceuticals Inc. Methods of treatment using furosemide
JP2024512650A (ja) 2021-04-02 2024-03-19 エスシーファーマシューティカルズ インコーポレイテッド フロセミドの皮下注入

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663348A (en) * 1985-07-02 1987-05-05 Warner-Lambert Co. Furosemide salts and pharmaceutical preparations thereof
US4698361A (en) 1986-05-28 1987-10-06 Schiena Michele G Di Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same
DE3623620A1 (de) * 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
WO1992021769A1 (en) * 1991-05-30 1992-12-10 Abbott Laboratories Reagents containing a nonspecific binding blocker in ion-capture binding assays
US5633240A (en) * 1994-09-01 1997-05-27 Academic Pharmaceuticals Parenteral solutions containing metolazone
EP0808171A2 (en) * 1995-02-10 1997-11-26 G.D. SEARLE & CO. Combination of angiotensin converting enzyme inhibitor, side-effect-reduced amount of aldosterone antagonist and diuretic
IT1283608B1 (it) * 1996-04-17 1998-04-22 Ricerche Di Schiena Snc Di Dr Composizione farmaceutica per la terapia orale diuretica ed antiipertensiva.
CN1068778C (zh) * 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
ATE409280T1 (de) 2005-12-28 2008-10-15 Sensile Pat Ag Mikropumpe
MX2009000385A (es) * 2006-07-12 2009-04-06 Univ Tennessee Res Foundation Acil-anilidas sustituidas y metodos de uso de las mismas.
EP2022518A1 (en) 2007-08-07 2009-02-11 Sensile Pat AG Modular drug delivery device for administering discrete doses of a medicament
US7923447B2 (en) * 2008-03-17 2011-04-12 Academic Pharmaceuticals Incorporated Parenteral solutions containing metolazone
CA2724540C (en) 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
EP2334302B1 (en) * 2008-09-09 2018-03-21 Cima Labs Inc DOSAGE FORMS FOR ACTIVE INGREDIENTS THAT ARE LOWLY IONIZABLE
US20110060280A1 (en) * 2009-09-04 2011-03-10 Sean Caffey Adhesive skin patch with pump for subcutaneous drug delivery
AU2012325801B2 (en) 2011-10-19 2016-05-12 Mercator Medsystems, Inc. Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation
PT2981258T (pt) 2013-04-05 2020-10-19 Scpharmaceuticals Inc Formulações farmacêuticas para administração subcutânea de furosemida
ES3041602T3 (en) * 2018-12-10 2025-11-13 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US11246851B2 (en) * 2019-01-04 2022-02-15 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
PH12021551811A1 (en) * 2019-01-31 2022-03-21 Scpharmaceuticals Inc Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
US12042709B1 (en) * 2022-02-22 2024-07-23 Craig E. Williams Fighting training device

Also Published As

Publication number Publication date
CN105431145B (zh) 2019-12-10
EP2981258A1 (en) 2016-02-10
BR112015025204A2 (pt) 2021-03-16
JP6415535B2 (ja) 2018-10-31
EP2981258B8 (en) 2020-11-11
US11433044B2 (en) 2022-09-06
US12370168B2 (en) 2025-07-29
MX2015014064A (es) 2017-04-13
US20160051507A1 (en) 2016-02-25
CN105431145A (zh) 2016-03-23
US20230201156A1 (en) 2023-06-29
DK2981258T3 (da) 2020-10-19
EP4696308A1 (en) 2026-02-18
KR102493735B1 (ko) 2023-01-30
HK1221152A1 (zh) 2017-05-26
JP6677779B2 (ja) 2020-04-08
AU2014248164B2 (en) 2019-05-23
KR20160014592A (ko) 2016-02-11
PT2981258T (pt) 2020-10-19
US9884039B2 (en) 2018-02-06
US20250339397A1 (en) 2025-11-06
WO2014165660A1 (en) 2014-10-09
JP2019001821A (ja) 2019-01-10
EP2981258A4 (en) 2016-10-05
EP3799869A1 (en) 2021-04-07
EP2981258B1 (en) 2020-08-12
EP3799869B1 (en) 2025-08-27
KR20210075211A (ko) 2021-06-22
SG10201709388QA (en) 2017-12-28
US20180303790A1 (en) 2018-10-25
IL241917B (en) 2020-10-29
CA2908935A1 (en) 2014-10-09
ES2823589T3 (es) 2021-05-07
KR102266460B1 (ko) 2021-06-17
US20200038364A1 (en) 2020-02-06
JP2016515623A (ja) 2016-05-30
AU2014248164A1 (en) 2015-10-15
US10272064B2 (en) 2019-04-30
CA2908935C (en) 2021-06-15
SG11201508251RA (en) 2015-11-27

Similar Documents

Publication Publication Date Title
MX2015014064A (es) Formulaciones farmaceuticas para administracion subcutanea de furosemida.
SG10201806539XA (en) Liquid protein formulations containing ionic liquids
MX2016005395A (es) Formulacion estable de insulina glulisina.
NZ711567A (en) Antibody formulations
BR112012018023A2 (pt) formulações líquidas que contêm anticorpo estabilizado.
MX2014004725A (es) Formulaciones de etanercept estabilizadas con aminoacidos.
EA201890417A1 (ru) Генетически кодируемые, внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения
BR112015000203A2 (pt) formulações de etanercept que exibem redução marcada em partículas sub-visíveis
MX2015010191A (es) Metodos para tratar infecciones microbianas, incluyendo mastitis.
CL2015003738A1 (es) Formulación líquida estable de amg-416 (velcalcetida)
TN2014000498A1 (en) Pharmaceutical formulation
IN2014DN08870A (https=)
PH12019502645A1 (en) Non-reversible humidity indicator card
MX2021001361A (es) Composicion liquida de fibrinogeno humano.
MD20170071A2 (ro) Compoziţii injectabile de paracetamol
MX369244B (es) Solucion alcoholica estable de alprostadilo.
MX2016008170A (es) Proteinas de fusion que comprenden factor ix para tratamiento profilactico de hemofilia y metodos para este.
UA85573U (ru) Способ нивелирования стресс-индуцированной гипергликемии при острых критических состояниях
MY177091A (en) Sterically stabilized palmitoleic acid liposome
UA95820U (uk) Комплексний препарат "ремівітал"
UA107945U (uk) Готовий лікарський засіб гіпоамоніємічної дії
IN2013CH01615A (https=)
HK1226323A1 (en) Liquid protein formulations containing ionic liquids

Legal Events

Date Code Title Description
FG Grant or registration